Iptacopan is named as an intervention in 16 current clinical trials in our China, USA, UK and India registers. 10 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Novartis Pharmaceuticals (14). The most-studied condition is Paroxysmal Nocturnal Hemoglobinuria.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Paroxysmal Nocturnal Hemoglobinuria | 2 |
| C3 Glomerulopathy | 1 |
| Immune-complex-membranoproliferative Glomerulonephritis | 1 |
| Primary IgA Nephropathy | 1 |
| Age-Related Macular Degeneration | 1 |
| Paroxysmal Nocturnal Hemoglobinuria (PNH) | 1 |
| Generalized Myasthenia Gravis | 1 |
| C3G | 1 |
| Atypical Hemolytic Uremic Syndrome | 1 |
| Lupus Nephritis | 1 |
| IC-MPGN | 1 |
| Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis | 1 |
| Glomerulonephritis, IGA | 1 |
| Immunoglobulin A Nephropathy | 1 |
| Primary Immunoglobulin A Nephropathy (IgAN) | 1 |
| Thrombotic Microangiopathy | 1 |
| Hematopoietic Stem Cell Transplantation (HSCT) | 1 |
| AIHA - Warm Autoimmune Hemolytic Anemia | 1 |
| AIHA - Cold Autoimmune Hemolytic Anemia | 1 |
| Lead sponsor | Trials |
|---|---|
| Novartis Pharmaceuticals | 14 |
| First Affiliated Hospital of Zhejiang University | 1 |
| Bing Han | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 13 | 7 |
| Clinical trials in USA | 12 | 7 |
| Clinical trials in UK | 10 | 5 |
| Clinical trials in India | 4 | 3 |
A trial with sites in more than one country appears in each of those registers.
16 current trials in our China, USA, UK and India registers name Iptacopan (also registered as LNP023) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 10 of the 16 trials are recruiting: 7 with sites in China, 7 with sites in USA, 5 with sites in UK and 3 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Novartis Pharmaceuticals (14), First Affiliated Hospital of Zhejiang University (1) and Bing Han (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Iptacopan works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Iptacopan works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Iptacopan (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.